Immunovant, Inc.

Informe acción NasdaqGS:IMVT

Capitalización de mercado: US$3.9b

Immunovant Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Immunovant de 8.3% y 75.5% por año respectivamente. Se prevé que el BPA crezca en un 11.2% al año. Se espera que la rentabilidad financiera sea de -175.9% en 3 años.

Información clave

8.3%

Tasa de crecimiento de los beneficios

11.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs28.3%
Tasa de crecimiento de los ingresos75.5%
Rentabilidad financiera futura-175.9%
Cobertura de analistas

Good

Última actualización20 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Jul 18
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

Jun 27

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12
Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30
Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:IMVT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
3/31/202752-547-401-35011
3/31/202620-494-441-42913
3/31/2025N/A-425-356-34813
9/30/2024N/A-323-272-272N/A
6/30/2024N/A-273-244-243N/A
3/31/2024N/A-259-215-214N/A
12/31/2023N/A-243-211-210N/A
9/30/2023N/A-255-210-210N/A
6/30/2023N/A-245-170-170N/A
3/31/2023N/A-211-188-188N/A
12/31/2022N/A-199-166-165N/A
9/30/2022N/A-177-151-151N/A
6/30/2022N/A-167-151-151N/A
3/31/2022N/A-157-106-106N/A
12/31/2021N/A-138-96-96N/A
9/30/2021N/A-128-87-87N/A
6/30/2021N/A-111-91-91N/A
3/31/2021N/A-107-84-83N/A
12/31/2020N/A-100-84-84N/A
9/30/2020N/A-79-66-65N/A
6/30/2020N/A-73-59-59N/A
3/31/2020N/A-66-53-53N/A
12/31/2019N/A-55-43-43N/A
9/30/2019N/A-52-46-46N/A
6/30/2019N/A-44-32-32N/A
3/31/2019N/A-29-29-29N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que IMVT siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que IMVT siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que IMVT siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (75.5% al año) de IMVT crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (75.5% al año) de IMVT crezcan más rápidamente que un 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: IMVT se prevé que no sea rentable en 3 años.


Descubre empresas en crecimiento